

## Novel associations of *BST1* and *LAMP3* with rapid eye movement sleep behavior disorder

Kheireddin Mufti, MSc<sup>1,2</sup>, Eric Yu, MSc<sup>1,2</sup>, BSc, Uladzislau Rudakou, MSc<sup>1,2</sup>, Lynne Krohn, MSc<sup>1,2</sup>, Jennifer A. Ruskey, MSc<sup>2,3</sup>, Farnaz Asayesh, MSc<sup>2,3</sup>, Sandra B. Laurent, BTS<sup>2,3</sup>, Dan Spiegelman, MSc<sup>2,3</sup>, Isabelle Arnulf, MD, PhD<sup>4</sup>, Michele T.M. Hu, MBBS, PhD<sup>5,6</sup>, Jacques Y. Montplaisir, MD, PhD<sup>7,8</sup>, Jean-François Gagnon, PhD<sup>7,9</sup>, Alex Desautels, MD, PhD<sup>7,10</sup>, Yves Dauvilliers, MD, PhD<sup>11</sup>, Gian Luigi Gigli, MD<sup>12,13</sup>, Mariarosaria Valente, MD<sup>12,14</sup>, Francesco Janes, MD, PhD<sup>12</sup>, Andrea Bernardini, MD<sup>12</sup>, Birgit Högl, MD<sup>15</sup>, Ambra Stefani, MD<sup>15</sup>, Evi Holzknacht, MD<sup>15</sup>, Karel Sonka, MD, PhD<sup>16</sup>, David Kemlink, MD, PhD<sup>16</sup>, Wolfgang Oertel, MD<sup>17</sup>, Annette Janzen, MD<sup>17</sup>, Giuseppe Plazzi, MD<sup>18,19</sup>, Elena Antelmi, MD, PhD<sup>20</sup>, Michela Figorilli, MD, PhD<sup>21</sup>, Monica Puligheddu, MD, PhD<sup>21</sup>, Brit Mollenhauer, MD<sup>22,23</sup>, Claudia Trenkwalder, MD<sup>22,23</sup>, Friederike Sixel-Döring, MD<sup>17,22</sup>, Valérie Cochen De Cock, MD, PhD<sup>24,25</sup>, Christelle Charley Monaca, MD, PhD<sup>26</sup>, Anna Heidbreder, MD<sup>27</sup>, Luigi Ferini-Strambi, MD<sup>28</sup>, Femke Dijkstra, MD<sup>29,30,31</sup>, Mineke Viaene, MD, PhD<sup>29,30</sup>, Beatriz Abril, MD<sup>32</sup>, Bradley F. Boeve, MD<sup>33</sup>, Jean-François Trempe, PhD<sup>34</sup>, Guy A. Rouleau, MD, PhD, FRCPC, FRSC<sup>1,2,3</sup>, Ronald B. Postuma, MD, MSc<sup>2,3,7</sup>, Ziv Gan-Or, MD, PhD<sup>1,2,3</sup>.

1. Department of Human Genetics, McGill University, Montréal, QC, Canada. 2. Montreal Neurological Institute, McGill University, Montréal, QC, Canada. 3. Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada. 4. Sleep Disorders Unit, Pitié Salpêtrière Hospital, Paris Brain Institute and Sorbonne University, Paris, France. 5. Oxford Parkinson's Disease Centre (OPDC), University of Oxford, Oxford, United Kingdom. 6. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom. 7. Center for Advanced Research in Sleep Medicine, Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'Île-de-Montréal – Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada. 8. Department of Psychiatry, Université de Montréal, Montréal, QC, Canada. 9. Department of Psychology, Université du Québec à Montréal, Montréal, QC, Canada. 10. Department of Neurosciences, Université de Montréal, Montréal, QC, H3T 1J4, Canada. 11. National Reference Center for Narcolepsy, Sleep Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Inserm U1061, Montpellier, France. 12. Clinical Neurology Unit, Department of Neurosciences, University Hospital of Udine, Udine, Italy. 13. DMIF, University of Udine, Udine, Italy. 14. Department of Medicine (DAME), University of Udine, Udine, Italy. 15. Sleep Disorders Clinic, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. 16. Department of Neurology and Centre of Clinical Neuroscience, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic. 17. Department of Neurology, Philipps University, Marburg, Germany. 18. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio-Emilia, Modena, Italy. 19. IRCCS, Institute of Neurological Sciences of Bologna, Bologna, Italy. 20. Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. 21. Department of Medical Sciences and Public Health, Sleep Disorder Research Center, University of Cagliari, Cagliari, Italy. 22. Paracelsus-Elena-Klinik, Kassel, Germany. 23. Department of Neurosurgery, University Medical Centre Göttingen, Göttingen, Germany. 24. Sleep and Neurology Unit, Beau Soleil Clinic, Montpellier, France. 25. EuroMov Digital Health in Motion, University of Montpellier IMT Mines Ales, Montpellier, France. 26. University Lille North of France, Department of Clinical Neurophysiology and Sleep Center, CHU Lille, Lille, France. 27. Department of Sleep Medicine and Neuromuscular Disorders, University of Münster, Münster, Germany. 28. Department of Neurological Sciences, Università Vita-Salute San Raffaele, Milan, Italy. 29. Laboratory for Sleep Disorders, St. Dimpna Regional Hospital, Geel, Belgium. 30. Department of Neurology, St. Dimpna Regional Hospital, Geel, Belgium. 31. Department of Neurology, University Hospital Antwerp, Edegem, Antwerp, Belgium. 32. Sleep disorder Unit, Carémeau Hospital, University Hospital of Nîmes, France. 33. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 34. Centre de Recherche en Biologie Structurale and Department of Pharmacology and Therapeutics, McGill University, Montréal, QC, Canada

**Corresponding author:**

Ziv Gan-Or  
Montreal Neurological Institute,  
McGill University  
1033 Pine Avenue, West,  
Ludmer Pavilion, room 312  
Montréal, QC, H3A 1A1,  
Phone: +1-514-398-5845, e-mail: [ziv.gan-or@mcgill.ca](mailto:ziv.gan-or@mcgill.ca)

**Counts:**

References: 34

Tables: 2

Supplementary tables: 7

Appendixes: 1

Figures: 1

Abstract – words: 249

Introduction – words: 249

Article – words: 3,771

Title – characters: 84

**Search Terms:**

1. Parkinson's disease
2. REM sleep behavior disorder
3. Association study
4. BST1
5. LAMP3

**Statistical review:** Ziv Gan-Or

**Study funding:**

This work was financially supported by the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), Parkinson Canada the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for

Healthy Lives (HBHL) program. The Montreal cohort was funded by the Canadian Institutes of Health Research (CIHR) and the W. Garfield Weston Foundation. The Oxford Discovery study is funded by the Monument Trust Discovery Award from Parkinson's UK and supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford, the NIHR Clinical Research Network and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN).

**Disclosures:**

Kheireddin Mufti – Reports no conflict of interest to disclose.

Eric Yu - Reports no conflict of interests to disclose.

Uladislau Rudakou - Reports no conflict of interests to disclose.

Lynne Krohn – Reports no conflict of interests to disclose.

Jennifer A. Ruskey – Reports no conflict of interests to disclose.

Farnaz Asayesh – Reports no conflict of interests to disclose.

Sandra B. Laurent – Reports no conflict of interests to disclose.

Dan Spiegelman – Reports no conflict of interests to disclose.

Isabelle Arnulf – Received fees for speaking engagements from UCB pharma, consultancy for Roche, Novartis, and Ono Pharma.

Michele T.M. Hu – Received consultancy fees from Roche and Biogen Pharmaceuticals.

Jacques Y. Montplaisir – Received consultancy fees from Eisai Co.

Jean-François Gagnon – Reports research funding from the Canadian Institutes of Health Research (CIHR).

Alex Desautels – Received grants from Flamel Ireland, Pfized, Biron, Canopy Growth, as well as fees for speaking engagements from Biogen and from consultancy from UCB pharma.

Yves Dauvilliers – Reports no conflict of interests to disclose.

Gian Luigi Gigli – Reports no conflict of interests to disclose.

Mariarosaria Valente – Reports no conflict of interests to disclose.

Francesco Janes - Reports no conflict of interests to disclose.

Andrea Bernardini - Reports no conflict of interests to disclose.

Birgit Högl – Received consultancy fees from Axovant, benevolent Bio, Takeda, Roche, ono, and received speaker honoraria from Eli Lilly, Mundipharma, UCB, Abbvie, Inspire, Lundbeck.

Ambra Stefani – Reports no conflict of interests to disclose.

Evi Holzknicht – Reports no conflict of interests to disclose.

Karel Sonka – Reports no conflict of interests to disclose.

David Kemlink – Reports no conflict of interests to disclose.

Wolfgang Oertel – Reports no conflict of interests related to the study. He received consultancy or speaker fees from Adamas, Abbvie, Desitin, Novartis and Roche. He has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung and Roche Pharma, Basel, Switzerland.

Annette Janzen – Reports no conflict of interests to disclose. She has received research funding from Parkinson Fonds Deutschland.

Giuseppe Plazzi – Reports no conflict of interests to disclose.

Elena Antelmi – Reports no conflict of interests to disclose.

Michela Figorilli – Reports no conflict of interests to disclose.

Monica Puligheddu – Reports no conflict of interests to disclose.

Brit Mollenhauer – Has received honoraria for consultancy from Roche, Biogen, UCB and Sun Pharma Advanced Research Company. BM is member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson's Research and has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung and the Michael J. Fox Foundation for Parkinson's Research.

Claudia Trenkwalder – Honoraria for lectures from UCB, Grünenthal, Otsuka and consultancy fees from Britannia Pharmaceuticals and Roche.

Friederike Sixel-Döring – Honoraria for lectures from Abbott, Desitin, Grünenthal, Licher MT, STADA Pharm, UCB. Seminar fees from Boston Scientific, Licher MT. Serves on an advisory board for STADA Pharm. No conflict of interest with the presented study.

Valérie Cochen De Cock – Reports no conflict of interests to disclose.

Christelle Charley Monaca – Reports no conflict of interests to disclose.

Anna Heidbreder – Reports no conflict of interests to disclose.

Luigi Ferini-Strambi – Reports no conflict of interests to disclose.

Femke Dijkstra – Reports no conflict of interests to disclose.

Mineke Viaene – Reports no conflict of interests to disclose.

Beatriz Abril – Reports no conflict of interests to disclose.

Bradley F. Boeve – Dr. Boeve has served as an investigator for clinical trials sponsored by Biogen and Alector. He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the LBD Functional Genomics Program.

Jean-François Trempe – Reports no conflict of interests to disclose.

Guy A. Rouleau – Reports no conflict of interests to disclose.

Ronald B. Postuma – Reports grants and Fonds de la Recherche en Sante, as well as grants from the Canadian Institute of Health Research, The Parkinson Society of Canada, the WestonGarfield Foundation, the Michael J. Fox Foundation, and the Webster Foundation, as well as personal fees from Takeda, Roche, Teva Neurosciences, Novartis Canada, Biogen, Boehringer Ingelheim, Theranexus, GE HealthCare, Jazz Pharmaceuticals, Abbvie, Janssen, Otsuko, Phytopharmics, and Inception Sciences.

Ziv Gan-Or – Received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali, Handl Therapeutics, Neuron23 and Deerfield.

## Abstract

**Objective:** To examine the role of genes identified through genome-wide association studies (GWASs) of Parkinson disease (PD) in the risk of isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD).

**Methods:** We fully sequenced 25 genes previously identified in GWASs of PD, in a total of 1,039 iRBD patients and 1,852 controls. The role of rare heterozygous variants in these genes was examined using burden tests. The contribution of biallelic variants was further tested. To examine the potential impact of rare nonsynonymous *BST1* variants on the protein structure, we performed *in silico* structural analysis. Finally, we examined the association of common variants using logistic regression adjusted for age and sex.

**Results:** We found an association between rare heterozygous nonsynonymous variants in *BST1* and iRBD ( $p=0.0003$  at coverage  $>50X$  and  $0.0004$  at  $>30X$ ), mainly driven by three nonsynonymous variants (p.V85M, p.I101V and p.V272M) found in 22 (1.2%) controls vs. two (0.2%) patients. All three variants seem to be loss-of-function variants with a potential effect on the protein structure and stability. Rare non-coding heterozygous variants in *LAMP3* were also associated with iRBD ( $p=0.0006$  at  $>30X$ ). We found no association between rare heterozygous variants in the rest of genes and iRBD. Several carriers of biallelic variants were identified, yet there was no overrepresentation in iRBD.

**Conclusion:** Our results suggest that rare coding variants in *BST1* and rare non-coding variants in *LAMP3* are associated with iRBD. Additional studies are required to replicate these results and examine whether loss-of-function of *BST1* could be a therapeutic target.

## Glossary

**AAO** = age at onset; **AAS** = age at sampling; **ACMSD** = Aminocarboxymuconate semialdehyde decarboxylase; **BST1** = Bone marrow stromal cell antigen 1; **CADD** = Combined Annotation Dependent Depletion; **CCDC62** = Coiled-coil domain containing 62; **CI** = confidence interval; **DOC** = depth of coverage; **F\_A** = frequency in affected; **F\_C** = frequency in control; **FGF20** = Fibroblast growth factor 20; **GAK** = Cyclin G associated kinase; **GATK** = Genome Analysis Toolkit; **GnomAD** = Genome Aggregation Database; **GPNUMB** = Glycoprotein (transmembrane) nmb; **GTEX** = Genotype-tissue expression; **GWAS** = genome-wide association study; **hg19** = human genome version 19; **HIP1R** = Huntingtin interacting protein 1 related; **iRBD** = isolated rapid-eye-movement sleep behavior disorder; **ITGA8** = Integrin subunit alpha 8; **LAMP3** = Lysosomal-associated membrane protein 3; **LD** = linkage disequilibrium; **LOF** = loss-of-function; **MAF** = minor allele frequency; **MAPT** = Microtubule-associated protein tau; **MCCCI** = Methylcrotonoyl-CoA carboxylase 1 ( $\alpha$ ); **MIPs** = molecular inversion probes; **NS** = non-synonymous; **OR** = odds ratio; **PCA** = principle component analysis; **PM20D1** = Peptidase M20 domain containing 1; **QC** = quality control; **QS** = quality score; **REM** = rapid eye movement; **RIT2** = Ras Like without CAAX 2; **SCARB2** = Scavenger receptor class B, member 2; **SETD1A** = SET domain containing 1A, histone lysine methyltransferase ; **SIPA1L2** = Signal induced proliferation associated 1 like 2; **SKAT** = sequence kernel association test; **SKAT-O** = optimized SKAT; **SLC41A1** = Solute carrier family 41 (magnesium transporter), member 1; **STK39** = Serine/threonine kinase 39; **STX1B** = Syntaxin 1B; **SYT11** = Synaptotagmin 11; **TMEM163** = Transmembrane protein 163; **USP25** = Ubiquitin specific peptidase 25; **UTR** = untranslated region; **vPSG** = video polysomnography.

## Introduction

Isolated rapid-eye-movement sleep behavior disorder (iRBD) is a prodromal synucleinopathy, as more than 80% of iRBD patients will eventually convert to Parkinson disease (PD, about 40-50% of patients), dementia with Lewy bodies (DLB) or unspecified dementia (40-50%), or, in much fewer cases, to multiple system atrophy (MSA, 5-10%).<sup>1, 2</sup> While our understanding of the genetic background of DLB or MSA is limited, there are 80 genetic loci found to be associated with PD risk discovered through genome-wide association studies (GWASs),<sup>3, 4</sup> and several genes have been implicated in familial PD.<sup>5-7</sup>

Recent studies have suggested that there is some overlap between the genetic backgrounds of iRBD and PD or DLB, yet this overlap is only partial. *GBA* variants are associated with iRBD risk, PD and DLB,<sup>5, 8</sup> but pathogenic *LRRK2* variants are only associated with PD, and not with iRBD and DLB.<sup>7, 9, 10</sup> *MAPT* and *APOE* haplotypes are important risk factors of PD and DLB, respectively,<sup>11, 12</sup> but neither are linked to iRBD.<sup>11, 13</sup> In the *SNCA* locus, specific variants in the 3' untranslated region (UTR) are associated with PD but not with iRBD, and other, independent variants at 5' UTR are associated with PD, iRBD and DLB.<sup>14</sup>

In the current study, we aimed to examine whether rare and common variants in 25 PD-related GWAS genes are associated with iRBD. Coding regions, exon-intron boundaries and 3' and 5' UTRs were fully captured and sequenced. We then performed different genetic analyses to investigate the association of these genes with iRBD.



## **Materials and methods**

### *Study population*

This study included a total of 2,891 subjects: 1,039 unrelated individuals who were diagnosed with iRBD (based on the International Classification of Sleep Disorders criteria, version 2 or 3) and 1,852 controls, all of European ancestry. The iRBD patients and controls were recruited through 18 centers in Canada and Europe, including centers from France, Germany, Austria, UK, Czech Republic, Italy, and Belgium. Diagnosis was performed with video polysomnography, the gold standard for iRBD diagnosis, by sleep specialists and neurologists. At recruitment, none of the patients had an overt neurodegenerative disease (PD, DLB, MSA etc.), which defined them as iRBD. In the current study, we had follow-up data available for 540 iRBD patients, 190 of which (35%) had converted since recruitment to PD, DLB or MSA or other overt neurodegenerative disease. The controls were not examined by polysomnography, but since only 1% of them is expected to develop iRBD, it is unlikely that this can affect the results. The European ethnicity of the participants was ascertained using GWAS data available in our lab, by performing principle component analysis and clustering with the European cohort available in HapMap v3. Details on age and on sex of the participants have been previously described,<sup>15</sup> and data available from Dryad (Table e-1): <https://doi.org/10.5061/dryad.vt4b8gtqd>. Differences in age and sex were taken into account as needed in the statistical analysis. All patients and controls were of European ancestry (principal component analysis [PCA] of GWAS data was used to confirm ancestry, as compared to data from HapMap v.3 and hg19/GRCh37).

### *Standard protocol approvals, registrations, and patient consents*

The study participants signed informed consent forms at enrollment to the study, and the institutional review boards have approved the study protocol.

### *Selection of genes and genetic analysis*

We designed and performed the study prior to the publication of the recent PD GWAS,<sup>3</sup> therefore, the genes for analysis were selected from previous GWASs.<sup>16, 17</sup> A total of 25 genes were selected for analysis, including: *ACMSD*, *BST1*, *CCDC62*, *DDRGK1*, *DGKQ*, *FGF20*, *GAK*, *GPNMB*, *HIP1R*, *ITGA8*, *LAMP3*, *MAPT*, *MCCC1*, *PM20D1*, *RAB25*, *RAB29*, *RIT2*, *SETD1A*, *SLC41A1*, *STK39*, *SIPA1L2*, *STX1B*, *SYT11*, *TMEM163* and *USP25*. We selected the genes due to at least one of the following reasons: the gene has a quantitative trait loci association, the gene is expressed in the human brain, the gene potentially interact with PD-associated genes, or the gene is involved in pathways implicated in PD, for example the autophagy-lysosomal pathway, mitochondria quality control and endolysosomal recycling. The 25 genes were fully captured (coding sequence and 3'- and 5'- untranslated regions) as reported previously with molecular inversion probes (MIPs).<sup>18</sup> The protocol is available on [https://github.com/gan-orlab/MIP\\_protocol](https://github.com/gan-orlab/MIP_protocol). Table e-2 details the probes used in the current study for the MIPs capture, data available from Dryad (Table e-2). Following the capture, we performed next-generation sequencing with the Illumina HiSeq 2500\4000 platform at the Génome Québec Innovation Centre. Sequencing reads were aligned to the hg19 reference genome using the Burrows-Wheeler Aligner.<sup>19</sup> We then used the Genome Analysis Toolkit (GATK, v3.8) for quality control and to call variants,<sup>20</sup> and ANNOVAR was used for variant annotation.<sup>21</sup> We extracted the variant frequencies for the detected variant from the Genome Aggregation Database (GnomAD).<sup>22</sup>

### *Quality control*

To perform quality control (QC), we used PLINK v1.9.<sup>23</sup> We excluded variants with a significant deviation (threshold set at  $p=0.001$ ) from Hardy-Weinberg equilibrium among controls. Variants with <25% of their reads with a variant call were also excluded. To filter out variants with low genotyping rate, we set the threshold for inclusion on >90%. This threshold was also used to exclude samples from individuals with low call rates. when missingness rate was different among patients and controls (at  $p<0.05$ ), we excluded these variants as well. variants with genotype quality score of <30 were further excluded. Rare variants (MAF 1%) were included based on two coverage thresholds, >30X and >50X, and all analyses were repeated using these thresholds. For the analysis of common variants, coverage of >15X was used.

### *Statistical analysis*

To test whether rare heterozygous variants (defined by  $MAF<0.01$ ) in each of our target genes are associated with iRBD, we performed sequence kernel association test (SKAT, R package)<sup>24</sup> and optimized SKAT (SKAT-O) on different groups of variants which included: all rare variants with  $MAF <1\%$ , variants which are potentially functional (including splicing, nonsynonymous, stop-gain and frame-shift variants), only loss-of-function variants (stop-gain, frame-shift and splicing), and only nonsynonymous variants. In addition, we further used the Combined Annotation Dependent Depletion (CADD) score to test whether rare variants that are predicted to be pathogenic (based on a threshold of  $\geq 12.37$  which represents 2% of the variants predicted to be the most deleterious) are enriched in iRBD patients. To test the association between biallelic

variants and iRBD risk, we used a threshold of MAF <0.1%, and examined whether there is enrichment of patients who carry two such variants compared to controls, using Fisher's exact test. Variants included in this analysis were either splice-site, nonsynonymous, stop-gain or frame-shift variants. To properly account for multiple comparisons, in each analysis we applied Bonferroni correction that took into consideration the number of genes that were tested, and that the tests were done in two different depths of coverage, >30X and >50X. Therefore, when examining the association of 25 genes in two different depths of coverage, the threshold for statistical significance in this case was set on  $p = 0.05/50 = 0.001$ . To test for association of common variants (MAF>0.01) we used logistic regression adjusting for sex and age, using PLINK v1.9. Linkage disequilibrium between the variants we found and the respective GWAS top hits was examined using the reference cohort of non-Finnish European embedded in LDlink (<https://ldlink.nci.nih.gov/>).<sup>25</sup> We used the genotype-tissue expression database (GTEx – <https://www.gtexportal.org>) to examine the effects of common variants on gene expression. We further performed in silico structural analysis of *BST1* to test whether the rare coding variants that were found to be associated with iRBD in our analysis could potentially affect the enzyme structure and activity. The atomic coordinates of human *BST1* bound to ATP- $\gamma$ -S were downloaded from the Protein Data Bank (ID 1lsg). We evaluated the steric clashes caused by the variants we identified using the “mutagenesis” toolbox in PyMol v. 2.2.0.

#### *Availability of data and materials*

Data after processing that was used for the analyses in the current study are found in the supplementary tables, data available from Dryad (Table e-1 - e-7):

<https://doi.org/10.5061/dryad.vt4b8gtqd>. The raw data can be requested from the corresponding author and will be shared anonymized.

## Results

### Coverage and identified variants

The average coverage of the 25 genes analyzed in this study was >647X (range 73-1162, median 790). An average of 95% of the target regions were covered with >15X, 93% with >30X and 90% with >50X. The average coverage of each gene and the percentage of the nucleotides covered at 15X, 30X and 50X are detailed in Table e-3, data available from Dryad (Table e-3). Finally, there were no differences in the coverage between patients and controls. A total of 1,189 rare variants were found with coverage of > 30X, and 570 rare variants with > 50X (data available from Dryad, Table e-4). We identified 125 common variants across all genes (data available from Dryad, Table e-5) with a coverage of >15X.

### Rare heterozygous variants in *BST1* and *LAMP3* are associated with iRBD

To examine whether rare heterozygous variants in our genes of interest may be associated with iRBD risk, we performed SKAT and SKAT-O tests, repeated twice for variants detected at depths of coverage of >30X and >50X (see methods). Table e-4 details all rare heterozygous variants identified in each gene and included in the analysis (data available from Dryad, Table e-4). We applied both SKAT and SKAT-O on five different groups of variants: all rare variants, all potentially functional variants (nonsynonymous, splice site, frame-shift and stop-gain), loss-of-function variants (frame-shift, stop-gain and splicing), nonsynonymous variants only, and variants with CADD score  $\geq 12.37$  (Table 1). The Bonferroni-corrected  $p$ -value threshold for statistical significance was set at  $p < 0.001$  after correcting for the number of genes and depths of coverage.

We found a statistically significant association of rare heterozygous functional variants in *BST1* (SKAT  $p=0.0004$  at  $>30X$  and  $p=0.0003$  at  $>50X$  for rare functional variants), found more in controls than in iRBD patients. This association is mainly driven by the nonsynonymous variants p.V85M (rs377310254, found in five controls and none in patients), p.I101V (rs6840615, found in seven controls and none in patients), and p.V272M (rs144197373, found in 10 controls and two patients). Overall, these variants were found in 22 (1.2%) controls vs. 2 (0.2%) patients. Of these two patients, one had self-reported age at onset of 25 years old (not confirmed by polysomnography at the time) and he was 75 years old at the time of the study, and did not convert to an overt synucleinopathy. The second patient had age at onset of 71 years old (compared to an average age at onset of 61 years in the entire cohort) and converted to DLB at the age of 73.

Another statistically significant association was found between rare variants in *LAMP3* gene and reduced iRBD risk in SKAT-O analysis. This association is driven by two non-coding variants (one intronic [location - chr3:182858302] and one at the 3' UTR of *LAMP3* [rs56682988, c.\*415T>C]) found only in controls (15 and nine controls, respectively). In order to further examine whether these variants indeed drive the association in both *BST1* and *LAMP3*, we excluded them and repeated the analysis (SKAT and SKAT-O), which resulted in loss of statistical significance for both genes (data available from Dryad, Table e-6). There were no additional statistically significant associations of the remaining genes with iRBD after correcting for multiple comparisons ( $p<0.001$ ). We also repeated the analysis in 350 patients with available data on conversion who did not convert at the time of the study (data available from Dryad, Table e-7). Rare functional and rare nonsynonymous *BST1* variants were nominally associated with iRBD ( $p=0.021$  and  $p=0.049$ , SKAT), but not after correction for multiple comparisons.

The association of *LAMP3* had a  $p=0.06$  (SKAT-O), demonstrating the reduced power in this smaller sub-population.

### **Structural analysis of *BST1* variants suggests that loss-of-function may be protective in iRBD**

To investigate the potential impact of the three *BST1* nonsynonymous variants (p.V85M, p.I101V and p.V272M) on the structure and activity of the enzyme, we performed *in silico* mutagenesis and evaluated potential clashes with surrounding residues. Figure 1 depicts the structure of *BST1* with the respective locations of the three nonsynonymous variants that drive the *BST1* association detected in our analysis. The structure of human *BST1* was solved by X-ray crystallography in complex with five substrate analogues<sup>26</sup>. All structures revealed a homodimeric assembly, with the catalytic clefts facing the cavity at the interface of the two chains (Figure 1A).

The sidechain of p.V85M points towards the hydrophobic core of the protein, behind a helix facing the nucleotide binding site. The amino-acid change from valine to the bulkier sidechain of methionine results in clashes with other residues in the core, for all rotamers (Figure 1B). This variant would therefore likely destabilize the enzyme active site and potentially unfold the protein. The sidechain of the variant p.I101V is located underneath the active site towards the hydrophobic core. Although the amino-acid change from isoleucine to the smaller sidechain of valine does not create clash (Figure 1C), it reduces the packing in the core, which could also destabilize the enzyme. Finally, the p.V272M variant is located in a helix at the C-terminus of the protein that forms symmetrical contacts with the same helix in the other chain of the dimer.



The p.V272M variant would create clashes with sidechain and main-chain atoms located in the other chain of the dimer (Figure 1D). As p.V272M resides at the dimer interface of the enzyme and probably helps maintaining the two subunits together, this variant would most likely lead to the disruption of the dimer. Overall, all the disease-associated nonsynonymous variants in *BST1* (p.V85M, p.I101V, and p.V272M) appear to be “loss-of-function”, suggesting that reduced *BST1* activity may be protective in iRBD. This is supported by the top PD GWAS hit in the *BST1* locus, the rs4698412 G allele, which is associated with reduced risk of PD<sup>3</sup>. This allele is also associated with reduced expression of *BST1* in blood in GTEx (normalized effect size = -0.07,  $p=1.5e-6$ ), suggesting that reduced expression might be protective.

### **Very rare bi-allelic variants are not enriched in iRBD patients**

In order to examine whether bi-allelic variants in our genes of interest are enriched in iRBD, we compared the carrier frequencies of very rare (MAF<0.001) homozygous and compound heterozygous variants between iRBD patients and controls. To analyze compound heterozygous variants, since phasing could not be performed, we considered carriers of two very rare variants as compound heterozygous carriers, with the following exceptions: 1) when variants were physically close (less than 112 base pairs [bp]; probes' target length) and we could determine their phase based on the sequence reads, and 2) if the same combination of very rare variants appeared more than once across samples, we assumed that the variants are most likely to be on the same allele. We found five (0.5%) iRBD patients and seven (0.4%) controls presumably carriers of bi-allelic variants in the studied genes (Table 2,  $p=0.731$ , Fisher test).

## Association of common variants in the target genes with iRBD

To test whether common variants in our target genes are associated with iRBD, we performed logistic regression (using PLINK v1.9 software) adjusted for age and sex for common variants (MAF>0.01) detected at coverage depth of >15X. A nominal association was observed in 12 variants across all genes (data available from Dryad, Table e-5), but no association remained statistically significant after Bonferroni correction for multiple comparisons (set at  $p<0.0005$ ).

Of the variants with nominal associations, one variant in the *ITGA8* 3' UTR (rs896435, OR=1.15, 95% CI = 1.01-1.32,  $p=0.04$ ) is the top hit from the most recent PD GWAS,<sup>3</sup> and two other *ITGA8* 3' UTR variants are almost in perfect LD ( $D'=1.0$ ,  $R^2>0.99$ ,  $p<0.0001$ ) with rs896435. Four variants in the 3' UTR of *RAB29* were almost in perfect LD (data available from Dryad, Table e-5) and are associated with expression of *RAB29* in multiple tissues in GTEx, including the brain. Three *MAPT* variants were in partial LD with PD GWAS hits in the *MAPT* locus and were associated with expression of multiple genes in multiple tissues in GTEx, demonstrating the complexity of this genomic region.

## Discussion

In the current study, we studied a large cohort of iRBD patients by fully-sequencing and analyzing 25 PD-related GWAS genes and their association with iRBD. Our results identify *BST1* and *LAMP3* as novel genes potentially associated with iRBD. Based on *in silico* models, the three nonsynonymous *BST1* variants that drive the association with iRBD may be loss-of-function variants, suggesting that reduced *BST1* activity may reduce the risk of developing iRBD. This hypothesis is further supported the results from the PD GWAS, in which the *BST1* locus variants were associated with reduced risk of PD were also associated with reduced

expression of *BST1*.<sup>3</sup> Further studies will be required to determine that these variants are indeed loss-of-function variants and to study the mechanism underlying this potential protective association. The variants driving the association of *LAMP3* are in noncoding regions and could be regulatory. These hypotheses will require confirmation in functional studies in relevant models. While some common variants were nominally associated with iRBD, none of them remained statistically significant after correction for multiple comparisons.

This study provides further support to our previous studies, showing that there is only partial overlap between the genetics of iRBD and PD. Genes that are important in PD such as *LRRK2* and *MAPT* seem to have no role in iRBD,<sup>10,11</sup> whereas other genes such as *GBA* are important in both, as well as in DLB.<sup>5, 8</sup> However, we cannot rule out that some of the 25 genes that we tested in the current study are associated with iRBD, yet the effect size of the association is too small to detect with the current sample size. Therefore, additional studies in larger cohorts of iRBD will be required in the future to fully uncover the association between PD-related genes and iRBD.

*BST1*, also called CD157, is a glycosyl phosphatidylinositol (GPI) anchored membrane protein initially found in bone marrow stromal cells and is essential for B-lymphocyte growth and development. It has an extracellular enzymatic domain that produces cyclic ADP-ribose (cADPR). This metabolite acts as a second messenger that can trigger  $\text{Ca}^{2+}$  release from intracellular stores,<sup>27</sup> a process that plays a role in cellular function and death. Specific features of calcium homeostasis have been suggested to be responsible for the specific vulnerability of dopaminergic neurons in PD,<sup>28</sup> yet whether *BST1* is involved in calcium homeostasis in human neurons is still unclear, as most work was done in non-human models. Another mechanism by which *BST1* may be involved in PD is immune response and neuroinflammation, which are

likely important in the pathogenesis of the disease. *BST1* serves as a receptor which regulates leukocyte adhesion and migration, and plays a role in inflammation.<sup>29</sup> However, its potential role in microglia activation and neuroinflammation is yet to be determined. Our *in-silico* analysis suggested that the *BST1* variants found mostly in controls are loss-of-function variants. Furthermore, common variants in the *BST1* locus, carried by >50% of the European population, are associated with reduced risk of PD in the most recent GWAS, and are also associated with reduced expression of *BST1* in blood,<sup>3</sup> indicating that reduced *BST1* expression may be protective. We can therefore hypothesize that these variants may reduce immune response and lead to a reduced risk of iRBD, and that inhibition of *BST1* could become a target for future preclinical drug discovery efforts for iRBD and PD treatment or prevention. Understanding the role of *BST1* as an immune response gene in iRBD, understanding the mechanism underlying this association, and examining whether it can serve as a target for early therapeutics development, will require additional research in humans and different models.

*LAMP3* encodes the lysosomal-associated membrane protein 3, which plays a role in the unfolded protein response (UPR) that contributes to protein degradation and cell survival during proteasomal dysfunction.<sup>30</sup> Furthermore, *LAMP3* knockdown impairs the ability of the cells to complete the autophagic process, and high *LAMP3* expression is associated with increased basal autophagy levels.<sup>31</sup> Numerous PD-related genes have been implicated in the autophagy-lysosomal pathway,<sup>32</sup> and genes associated with iRBD such as *GBA*,<sup>33</sup> *TMEM175*<sup>34</sup> and *SNCA*<sup>14</sup> are all involved in this pathway. Our current findings further strengthen the potential association between the autophagy-lysosomal pathway and iRBD. The specific role of *LAMP3* in this pathway and how it may be involved in iRBD and the subsequent synucleinopathies will require

additional studies. Since the rare variants we identified were found only in controls, it may suggest that *LAMP3* may have a protective effect that should be further explored.

Our study has several limitations. First, despite being the largest genetic study of iRBD to date, it may be still underpowered to detect rare variants in GWAS PD-related genes, as well as common variants with a small effect size. Therefore, we cannot completely rule out the possibility that rare and common variants in these genes may contribute to iRBD risk. A second limitation is the younger age and the differences in sex distribution between iRBD patients and controls, for which we adjusted in the statistical analysis as needed. Another potential limitation is the possibility that there were undiagnosed iRBD patients among the control population. However, since iRBD is found in only ~1% of the population,<sup>1</sup> the effect of having undiagnosed iRBD patients in the controls would be minimal, given the large sample size. Additional limitation is the lack of replication cohort; therefore, our findings should be replicated in additional iRBD cohorts once they become available. Lastly, our study includes only individuals of European descent, and fully understanding the genetics of iRBD will require studies with other ethnicities. Unfortunately, due to the reduced availability of polysomnography in many countries, there are currently only very few small cohorts of iRBD patients from other populations, and more effort is required to develop such cohorts in different countries.

To conclude, our results suggest two novel genetic associations with iRBD; an association with rare functional variants in *BST1*, and with rare non-coding variants in *LAMP3*. All the association-driving coding variants found in *BST1*, mainly in controls, appear to potentially cause loss-of-function, suggesting that reduced *BST1* activity may reduce the risk of iRBD. Further studies would be required to confirm our results and to examine the biological mechanism underlying the effect of disease-associated variants in both *LAMP3* and *BST1*. The

absence of evidence of association between rare and common variants in the remaining genes and iRBD risk suggests that these genes either have no effect in iRBD or have a minor effect that we could not detect with this sample size. Environmental factors and environment-gene interactions are likely to play a major role on iRBD, and larger studies that include carefully collected epidemiological data and more extensive genetic data such as whole-exome or whole-genome sequencing will be required to clarify these issues.

### **Acknowledgments**

We thank the participants for contributing to this study. JYM holds a Canada Research Chair in Sleep Medicine. JFG holds a Canada Research Chair in Cognitive Decline in Pathological Aging. WO is Hertie Senior Research Professor, supported by the Hertie Foundation. EAF holds a Canada Research Chair (Tier 1) in Parkinson disease. GAR holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Pen field Chair in Neurosciences. JFT holds a Canada Research Chair (Tier 2) in Structural Pharmacology. ZGO is supported by the Fonds de recherche du Québec–Santé Chercheur-Boursier award and is a Parkinson Canada New Investigator awardee. We thank D. Rochefort, H. Catoire, and V. Zaharieva for their assistance.

## References

1. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain* 2019;142:744-759.
2. Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. *The Lancet Neurology* 2016;15:405-419.
3. Nalls MA, Blauwendraat C, Vallerga CL, et al. Expanding Parkinson's disease genetics: novel risk loci, genomic context, causal insights and heritable risk. *BioRxiv* 2019:388165.
4. Foo JN, Chew EGY, Chung SJ, et al. Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. *JAMA neurology* 2020.
5. Gan-Or Z, Rouleau GA. Genetics of REM Sleep Behavior Disorder. *Rapid-Eye-Movement Sleep Behavior Disorder*: Springer, 2019: 589-609.
6. Gan-Or Z, Alcalay RN, Rouleau GA, Postuma RB. Sleep disorders and Parkinson disease; lessons from genetics. *Sleep medicine reviews* 2018;41:101-112.
7. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. *The Lancet Neurology* 2020;19:170-178.
8. Gan-Or Z, Mirelman A, Postuma RB, et al. GBA mutations are associated with rapid eye movement sleep behavior disorder. *Ann Clin Transl Neurol* 2015;2:941-945.
9. Heckman MG, Soto-Ortolaza AI, Contreras MYS, et al. LRRK2 variation and dementia with Lewy bodies. *Parkinsonism & related disorders* 2016;31:98-103.
10. Bencheikh BOA, Ruskey JA, Arnulf I, et al. LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. *Parkinsonism & related disorders* 2018;52:98-101.
11. Li J, Ruskey JA, Arnulf I, et al. Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder. *Movement Disorders* 2018;33:1016-1020.
12. Dickson DW, Heckman MG, Murray ME, et al. APOE  $\epsilon$ 4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. *Neurology* 2018;91:e1182-e1195.
13. Gan-Or Z, Montplaisir JY, Ross JP, et al. The dementia-associated APOE  $\epsilon$ 4 allele is not associated with rapid eye movement sleep behavior disorder. *Neurobiology of aging* 2017;49:218. e213-218. e215.
14. Krohn L, Wu RY, Heilbron K, et al. Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. *Annals of Neurology* 2020;87:584-598.
15. Mufti K, Rudakou U, Yu E, et al. A comprehensive analysis of dominant and recessive parkinsonism genes in REM sleep behavior disorder. *medRxiv* 2020.
16. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nature genetics* 2014;46:989.
17. Chang D, Nalls MA, Hallgrímsson IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nature genetics* 2017;49:1511.
18. O'Roak BJ, Vives L, Fu W, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science* 2012;338:1619-1622.
19. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *bioinformatics* 2009;25:1754-1760.
20. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome research* 2010;20:1297-1303.
21. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic acids research* 2010;38:e164-e164.
22. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285-291.

23. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *The American journal of human genetics* 2007;81:559-575.
24. Lee S, Emond MJ, Bamshad MJ, et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. *The American Journal of Human Genetics* 2012;91:224-237.
25. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics* 2015;31:3555-3557.
26. Yamamoto-Katayama S, Ariyoshi M, Ishihara K, Hirano T, Jingami H, Morikawa K. Crystallographic studies on human BST-1/CD157 with ADP-ribosyl cyclase and NAD glycohydrolase activities. *Journal of molecular biology* 2002;316:711-723.
27. Ishihara K, Hirano T. BST-1/CD157 regulates the humoral immune responses in vivo. *Chemical immunology* 2000;75:235-255.
28. Chan CS, Gertler TS, Surmeier DJ. Calcium homeostasis, selective vulnerability and Parkinson's disease. *Trends in neurosciences* 2009;32:249-256.
29. Malavasi F, Deaglio S, Ferrero E, et al. CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. *Molecular medicine*; 2006: BioMed Central: 334-341.
30. Dominguez-Bautista JA, Klinkenberg M, Brehm N, et al. Loss of lysosome-associated membrane protein 3 (LAMP3) enhances cellular vulnerability against proteasomal inhibition. *European journal of cell biology* 2015;94:148-161.
31. Nagelkerke A, Sieuwerts AM, Bussink J, et al. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. *Endocr Relat Cancer* 2014;21:101-112.
32. Senkevich K, Gan-Or Z. Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. *Parkinsonism & Related Disorders* 2019.
33. Krohn L, Ruskey JA, Rudakou U, et al. GBA variants in REM sleep behavior disorder: a multicenter study. *Neurology* 2020.
34. Krohn L, Öztürk TN, Vanderperre B, et al. Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. *Annals of Neurology* 2020;87:139-153.



## Figure legends

### Figure 1. Structural analysis of human *BST1* variants

This figure was produced using the software PyMOL v.2.2.0, and represents: (A) Structure of the BST1 dimer bound to ATP- $\gamma$ S (pdb 1ISG). The position of each variant sites is indicated. The ATP- $\gamma$ S molecule in the active site is shown as sticks. (B) Close-up view of the p.V85M variant site. The mutated residue is shown in white. The variant would create clashes (red disks) with nearby Ala77 in the core. (C) Close-up view of the p.I101V variant site. The residue is located in the core of the protein, but the variant to a smaller residue results in no clash. (D) Close-up view of the p.V272M variant site. Primed (') residues correspond to chain B. This residue is located at the dimer interface and the variant would create clashes with the other chain resulting in a destabilization of the dimer.

Tables

Table 1. Summary of results from burden analyses of rare heterozygous variants

DOC	Gene	All rare ( <i>p</i> -value)		Rare functional ( <i>p</i> -value)		Rare LOF ( <i>p</i> -value)		Rare NS ( <i>p</i> -value)		Rare CADD ( <i>p</i> -value)	
		SKAT-O	SKAT Burden	SKAT-O	SKAT Burden	SKAT-O	SKAT Burden	SKAT-O	SKAT Burden	SKAT-O	SKAT Burden
30x	<i>ACMSD</i>	0.124	0.788	0.101	0.475	NV	NV	0.101	0.475	0.098	0.299
	<i>BSTI</i>	0.040	0.020	<b>0.0009</b>	<b>0.0004</b>	0.348	0.653	0.001	<b>0.0007</b>	0.011	0.005
	<i>CCDC62</i>	0.006	0.357	0.048	0.975	0.080	0.596	0.282	0.203	0.134	0.074
	<i>DDRGKI</i>	0.152	0.112	0.745	0.527	0.765	0.587	0.746	0.742	0.919	0.677
	<i>DGKQ</i>	0.067	0.062	0.067	0.062	NV	NV	0.183	0.188	NV	NV
	<i>FGF20</i>	0.059	0.020	0.142	0.552	0.162	0.149	0.162	0.149	0.052	0.041
	<i>GAK</i>	0.195	0.836	0.386	0.565	0.885	0.642	0.781	0.613	0.701	0.684
	<i>GPNMB</i>	0.189	0.798	0.311	0.205	0.547	0.665	0.447	0.304	0.530	0.348
	<i>HIP1R</i>	0.166	0.940	0.219	0.609	NV	NV	0.072	0.993	0.056	0.671
	<i>ITGA8</i>	0.282	0.726	0.379	0.945	0.346	0.648	0.382	0.997	0.288	0.873
	<i>LAMP3</i>	<b>0.0006</b>	0.478	0.189	0.322	0.787	0.300	0.318	0.724	0.524	0.601
	<i>MAPT</i>	0.063	0.132	0.003	0.001	1	1	0.063	0.037	0.165	0.101
	<i>MCCCI</i>	0.426	0.413	0.303	0.743	0.347	0.649	1	0.866	0.886	0.690
	<i>PM20D1</i>	0.333	0.463	0.844	0.643	0.674	0.464	0.645	0.479	0.569	0.416
	<i>RAB25</i>	0.561	0.395	0.807	0.802	0.777	0.968	0.565	0.637	NV	NV
	<i>RAB29</i>	0.252	0.222	0.660	0.425	NV	NV	0.777	0.967	0.777	0.967
	<i>RIT2</i>	0.395	0.242	0.023	0.266	NV	NV	0.576	0.495	0.576	0.495
	<i>SETD1A</i>	0.667	0.500	0.241	0.452	0.171	0.166	0.300	0.940	0.310	0.399
	<i>SLC41A1</i>	0.073	0.167	0.055	0.031	0.060	0.065	0.754	0.433	0.257	0.213
	<i>STK39</i>	0.098	0.789	0.055	0.094	0.174	0.171	0.160	0.247	0.160	0.247
<i>SIPA1L2</i>	0.024	0.095	0.028	0.176	0.886	0.806	0.032	0.379	0.044	0.084	
<i>STX1B</i>	0.504	0.682	NV	NV	NV	NV	NV	NV	NV	NV	
<i>SYT11</i>	0.365	0.887	0.737	0.582	1	1	0.673	0.465	0.673	0.465	
<i>TMEM163</i>	0.598	0.411	0.170	0.165	NV	NV	0.170	0.165	0.170	0.165	
<i>USP25</i>	0.012	0.325	0.102	0.150	NV	NV	0.048	0.067	0.052	0.096	
50x	<i>ACMSD</i>	0.127	0.538	0.102	0.188	NV	NV	0.102	0.188	0.087	0.093
	<i>BSTI</i>	0.018	0.009	<b>0.0007</b>	<b>0.0003</b>	0.671	0.470	0.001	<b>0.0009</b>	0.010	0.006
	<i>CCDC62</i>	0.011	0.012	0.031	0.018	0.056	0.047	0.027	0.014	0.005	0.004
	<i>DDRGKI</i>	0.368	0.314	0.899	0.811	NV	NV	0.899	0.811	0.899	0.811
	<i>DGKQ</i>	NV	NV	NV	NV	NV	NV	NV	NV	NV	NV
	<i>FGF20</i>	0.015	0.030	0.164	0.153	0.164	0.153	NV	NV	0.164	0.153
	<i>GAK</i>	0.195	0.836	0.386	0.565	0.885	0.642	0.781	0.613	0.701	0.684
	<i>GPNMB</i>	0.046	0.995	0.177	0.127	0.108	0.413	0.343	0.215	0.283	0.189
	<i>HIP1R</i>	NV	NV	NV	NV	NV	NV	NV	NV	NV	NV
	<i>ITGA8</i>	0.184	0.315	0.402	0.540	0.340	0.634	0.428	0.584	0.345	0.942
	<i>LAMP3</i>	0.004	0.930	0.047	0.458	0.785	0.304	0.020	0.016	0.458	0.513
	<i>MAPT</i>	0.605	0.503	0.619	0.659	NV	NV	0.619	0.659	0.619	0.659
	<i>MCCCI</i>	0.26	0.151	0.972	0.752	0.334	0.618	0.951	0.745	0.958	0.800
	<i>PM20D1</i>	0.903	0.934	0.873	0.758	0.662	0.487	1	0.758	0.816	0.666
	<i>RAB25</i>	0.173	0.169	NV	NV	NV	NV	NV	NV	NV	NV
	<i>RAB29</i>	NV	NV	NV	NV	NV	NV	NV	NV	NV	NV
	<i>RIT2</i>	0.953	0.874	0.667	0.478	NV	NV	0.667	0.478	0.667	0.478
	<i>SETD1A</i>	0.212	0.147	0.671	0.469	NV	NV	0.671	0.469	0.671	0.469
	<i>SLC41A1</i>	0.132	0.189	NV	NV	NV	NV	NV	NV	NV	NV
	<i>STK39</i>	0.073	0.808	0.051	0.087	0.160	0.146	0.160	0.146	0.160	0.146
<i>SIPA1L2</i>	0.163	0.098	0.598	0.861	NV	NV	0.777	0.963	0.777	0.963	
<i>STX1B</i>	NV	NV	NV	NV	NV	NV	NV	NV	NV	NV	
<i>SYT11</i>	0.0896	0.671	0.672	0.467	NV	NV	NV	NV	NV	NV	
<i>TMEM163</i>	0.308	0.237	0.169	0.163	NV	NV	0.169	0.163	0.169	0.163	
<i>USP25</i>	0.127	0.418	0.027	0.019	NV	NV	0.027	0.019	0.069	0.037	

The table shows  $p$ -values of the SKAT and SKAT-O analysis in the specified subgroups; in bold - result significant after Bonferroni correction for the number of genes and depths; DOC: Depth of coverage; LOF: Loss of function; NS: Nonsynonymous; CADD: Combined annotation dependent depletion; SKAT-O: Optimized sequence kernel association test; SKAT: Kernel association test; NV: No variants were found for this filter.

**Table 2. Summary of all samples carrying two nonsynonymous variants detected in the present study**

Gene	Sample	Sex	AAS/ AAO	dbSNP	Allele*	Substitution	F_A	F_C	gnomAD	gnomAD
									ALL	NFE
<i>GPNMB</i>	A	M	75/50	7:23300122	T/C	p.S250P	0.000528	0	-	-
				7:23313795	G/T	p.Q545H	0.0005285	0	-	-
<i>MAPT</i>	A	M	85/66	17:44051771	G/T	p.D81Y	0.0005656	0	-	-
				rs63750612	G/A	p.A120T	0.0005423	0	0.0035	7.17E-05
<i>SIPAIL2</i>	A	F	64/48	rs184013125	G/A	p.S1482L	0.002665	0.008451	0.0057	0.0092
				rs200917620	G/A	p.R1089W	0.000547	0.000293	9.44E-05	0.0002
<i>SIPAIL2</i>	A	F	66/-	rs184013125	G/A	p.S1482L	0.002665	0.008451	0.0057	0.0092
				rs200293380	C/T	p.D1088N	0.006031	0.004695	0.0028	0.0041
<i>USP25</i>	A	M	68/-	rs377694221	C/T	p.A56V	0.000533	0	5.35E-05	7.23E-05
				rs200059109	G/T	p.D815Y	0.000533	0	0.0002	1.90E-05
<i>MCCCI</i>	C	M	35	rs149017703	C/T	p.G648S	0.001063	0.001683	0.0005	0.0009
				3:182810207	T/G	p.H88P	0	0.0002804	8.12E-06	8.95E-06
<i>PM20D1</i>	C	M	50	rs145195839	G/A	p.A332V	0.001059	0.000844	0.0003	0.0004
				rs14160575	G/T	p.P281Q	0.005325	0.005936	0.0057	0.0058
<i>SIPAIL2</i>	C	M	48	1:232615440		p.Y673F	0	0.0002817	-	-
				rs761063595		p.S266N	0	0.0002817	4.07E-06	8.99E-06
<i>SIPAIL2</i>	C	M	-	rs61729754	T/G	p.M1427L	0.009062	0.005634	0.0058	0.0088
				rs200293380	C/T	p.D1088N	0.006031	0.004695	0.0028	0.0041
<i>SIPAIL2</i>	C	M	28	rs184013125	G/A	p.S1482L	0.002665	0.008451	0.0057	0.0092
				1:232581435	T/C	p.T1065A	0	0.000282	-	-
<i>SIPAIL2</i>	C	M	50	rs184013125	G/A	p.S1482L	0.002665	0.008451	0.0057	0.0092
				rs966761148	C/T	p.V822M	0	0.000282	2.03E-05	2.69E-05

The table represents all the carriers of biallelic nonsynonymous variants in the target genes; A: Affected; C: Control; M: Male; F: Female; AAS: Age at sampling; AAO: Age at onset of iRBD; dbSNP: Single nucleotide polymorphism database; \*Allele: Reference allele/mutant allele; F\_A: Frequency in affected; F\_C: Frequency in controls; gnomAD ALL: Exome allele frequency in all populations; gnomAD NFE: Exome allele frequency in non-Finnish European.

## Appendix 1 Authors

<b>Name</b>	<b>Location</b>	<b>Role</b>	<b>Contribution</b>
<b>Kheireddin Mufti, MSc</b>	McGill University, QC, Canada	Author	Designed and conceptualized study; analyzed the data; drafted the manuscript for intellectual content
<b>Eric Yu, BSc</b>	McGill University, QC, Canada	Author	Analyzed the data; revised the manuscript for intellectual content
<b>Uladislau Rudakou, MSc</b>	McGill University, QC, Canada	Author	Analyzed the data; revised the manuscript for intellectual content
<b>Lynne Krohn, MSc</b>	McGill University, QC, Canada	Author	Analyzed the data; revised the manuscript for intellectual content
<b>Jennifer A. Ruskey, MSc</b>	McGill University, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Farnaz Asayesh, MSc</b>	McGill University, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Sandra B. Laurent, BTS</b>	McGill University, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Dan Spiegelman, MSc</b>	McGill University, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Isabelle Arnulf, MD, PhD</b>	Moelle Epinière and Sorbonne Universities, Paris, France	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Michele T.M. Hu,</b>	Oxford University, Oxford, UK	Author	Major role in the acquisition of data;

<b>MBBS, FRCP, PhD</b>			revised the manuscript for intellectual content
<b>Jacques Y. Montplaisir, MD, PhD</b>	Université de Montréal, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Jean-François Gagnon, PhD</b>	Hôpital du Sacré-Coeur de Montréal, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Alex Desautels, MD, PhD</b>	Université de Montréal, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Yves Dauvilliers, MD, PhD</b>	University of Montpellier, Montpellier, France	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Gian Luigi Gigli, MD</b>	University Hospital of Udine, Udine, Italy	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Mariarosaria Valente, MD</b>	University Hospital of Udine, Udine, Italy	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Francesco Janes, MD, PhD</b>	University Hospital of Udine, Udine, Italy	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Andrea Bernardini, MD</b>	University Hospital of Udine, Udine, Italy	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Birgit Högl, MD</b>	Medical University of Innsbruck,	Author	Major role in the acquisition of data;

	Innsbruck, Austria		revised the manuscript for intellectual content
<b>Ambra Stefani, MD</b>	Medical University of Innsbruck, Innsbruck, Austria	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Evi Holzknrecht, MD</b>	Medical University of Innsbruck, Innsbruck, Austria	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Karel Sonka, MD, PhD</b>	Charles University, Prague, Czech Republic	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>David Kemlink, MD, PhD</b>	Charles University, Prague, Czech Republic	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Wolfgang Oertel, MD</b>	Philipps University, Marburg, Germany	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Annette Janzen, MD</b>	Philipps University, Marburg, Germany		Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Giuseppe Plazzi, MD</b>	University of Bologna, Bologna, Italy	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Elena Antelmi, MD, PhD</b>	University of Bologna, Bologna, Italy	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Michela Figorilli, PhD</b>	University of Cagliari, Cagliari,	Author	Major role in the acquisition of data;

	Italy		revised the manuscript for intellectual content
<b>Monica Puligheddu, MD</b>	University of Cagliari, Cagliari, Italy	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Brit Mollenhauer, MD</b>	University Medical Centre Göttingen, Göttingen, Germany	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Claudia Trenkwalder, MD</b>	University Medical Centre Göttingen, Göttingen, Germany	Author	Major role in the acquisition of data; revised the manuscript for intellectual content.
<b>Friederike Sixel-Döring, MD</b>	University Medical Centre Göttingen, Göttingen, Germany	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Valérie Cochen De Cock, PhD</b>	University Medical Centre Göttingen, Göttingen, Germany	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Christelle Charley Monaca, MD</b>	University Lille North of France, Lille, France	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Anna Heidbreder, MD</b>	University of Münster, Münster, Germany	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Luigi Ferini-Strambi, MD</b>	Università Vita-Salute San Raffaele, Milan, Italy	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Femke Dijkstra, MD</b>	St. Dimpna Regional Hospital,	Author	Major role in the acquisition of data;



	Geel, Belgium		revised the manuscript for intellectual content
<b>Mineke Viaene, MD, PhD</b>	St. Dimpna Regional Hospital, Geel, Belgium	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Beatriz Abril, MD</b>	University Hospital of Nîmes, France	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Bradley F. Boeve, MD</b>	Mayo Clinic, Rochester, MN, USA	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Jean-François Trempe, PhD</b>	McGill University, QC, Canada	Author	Analyzed the data; revised the manuscript for intellectual content
<b>Guy A. Rouleau MD, PhD, FRCPC</b>	McGill University, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Ronald B. Postuma, MD, MSc</b>	McGill University, QC, Canada	Author	Major role in the acquisition of data; revised the manuscript for intellectual content
<b>Ziv Gan-Or, MD, PhD</b>	McGill University, QC, Canada	Author	Designed and conceptualized study; major role in the acquisition of data; drafted the manuscript for intellectual content

